Clinical trials: Inactivity
Hepatitis B, Chronic
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
- Trial name
- NCT04684914
- Testing
- HepTcell
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Altimmune, Inc.
Melasma
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects…
- Trial name
- NCT00669071
- Testing
- Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Galderma R&D
Endometriosis
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
The purpose of this study is to assess safety and efficacy of BAY 1817080 compared to elagolix and placebo in women with symptomatic endometriosis.
- Trial name
- SCHUMANN (NCT04614246)
- Testing
- BAY1817080, Elagolix
- Where
- 147 sites in United States, Austria and 18 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled.
- Trial name
- NCT04583735
- Testing
- TEPEZZA
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Amgen
Uveitis
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- Trial name
- Visual II (NCT01124838)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 261 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis
- Trial name
- ASLeap (NCT03350815)
- Testing
- 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
- Where
- 65 sites in United States
- Volunteers
- 322 people
- Sponsor
- Novartis Pharmaceuticals
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Male Idiopathic Infertility
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH)…
- Trial name
- NCT05403476
- Testing
- FE 999049
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
Interstitial Cystitis, Painful Bladder Syndrome
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
- Trial name
- NCT00919113
- Testing
- 2% sodium chondroitin sulfate
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Watson Pharmaceuticals